PurposeofReview Inadditiontoassistinginachievingimprovedglucosecontrol,continuousglucosemonitoring(CGM)sensor technologymay also aid in detection and preventionof hypoglycemia. In this paper, we report onthe current scientificevidence on the effectiveness of this technology in the prevention of severe hypoglycemia and hypoglycemia unawareness. Recent Findings Recent studies have found that the integration of CGM with continuous subcutaneous insulin infusion (CSII) therapy,asystemknownassensor-augmentedpump(SAP)therapy,verysignificantlyreducestheoccurrenceoftheseconditions by providing real-time glucose readings/trends and automatically suspending insulin infusion when glucose is low (LGS) or, even,beforeglucoseislowbutispredictedtosoonbelow(PLGS).Initialdataindicatethatevenforpatientswithtype1diabetes treated with multiple daily injections, real-time CGM alone has been found to reduce both severe hypoglycemia and hypoglycemiaunawareness.Closedloopsystems(artificialpancreas) comprisedofCGMandCSIIwithoutpatient interventiontoadjust basalinsulin,whichautomaticallyreduce,increase,andsuspendinsulindelivery,representapotentialnewoptionthatismoving toward becoming a reality in the near future. Summary Sensor technology promises to continue to improve patients’ lives not only by attaining glycemic control but also by reducing hypoglycemia, a goal best achieved in conjunction with structured individualized patient education.
Prevention and Management of Severe Hypoglycemia and Hypoglycemia Unawareness: Incorporating Sensor Technology
Lucidi, Paola;Porcellati, Francesca;Bolli, Geremia B.;Fanelli, Carmine G.
2018
Abstract
PurposeofReview Inadditiontoassistinginachievingimprovedglucosecontrol,continuousglucosemonitoring(CGM)sensor technologymay also aid in detection and preventionof hypoglycemia. In this paper, we report onthe current scientificevidence on the effectiveness of this technology in the prevention of severe hypoglycemia and hypoglycemia unawareness. Recent Findings Recent studies have found that the integration of CGM with continuous subcutaneous insulin infusion (CSII) therapy,asystemknownassensor-augmentedpump(SAP)therapy,verysignificantlyreducestheoccurrenceoftheseconditions by providing real-time glucose readings/trends and automatically suspending insulin infusion when glucose is low (LGS) or, even,beforeglucoseislowbutispredictedtosoonbelow(PLGS).Initialdataindicatethatevenforpatientswithtype1diabetes treated with multiple daily injections, real-time CGM alone has been found to reduce both severe hypoglycemia and hypoglycemiaunawareness.Closedloopsystems(artificialpancreas) comprisedofCGMandCSIIwithoutpatient interventiontoadjust basalinsulin,whichautomaticallyreduce,increase,andsuspendinsulindelivery,representapotentialnewoptionthatismoving toward becoming a reality in the near future. Summary Sensor technology promises to continue to improve patients’ lives not only by attaining glycemic control but also by reducing hypoglycemia, a goal best achieved in conjunction with structured individualized patient education.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
